Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals

Current Hypertension Reports

Volumn 15, Issue 3, 2013, Pages 260-267

  Cicero, Arrigo F G ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Blood pressure; BP; Clinical evidence; Dietary supplements; Hypertension; Nutraceuticals; Review

Indexed keywords

ACETYLCYSTEINE; AMLODIPINE; ARGININE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; GARLIC EXTRACT; GRAPE SEED EXTRACT; HERBACEOUS AGENT; ISOFLAVONE; LACTOTRIPEPTIDE; LYCOPENE; MAGNESIUM; MELATONIN; PLACEBO; POLYUNSATURATED FATTY ACID; PYCNOGENOL; PYRIDOXINE; RESVERATROL; TAURINE; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; ZINC;

ARTICLE; BLACK SESAME; CACAO; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DIETARY FIBER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FISH MEAT; GASTROINTESTINAL SYMPTOM; HIBISCUS SABDARIFFA; HUMAN; HYPERTENSION; NUTRIENT MANAGEMENT; OPTIMAL DRUG DOSE; POMEGRANATE JUICE; POTASSIUM INTAKE; RISK BENEFIT ANALYSIS; SESAME; TREATMENT DURATION;

ANTIOXIDANTS; BLOOD PRESSURE; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; UBIQUINONE;

EID: 84877805850     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0333-8     Document Type: Article

References (88)

1. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112:3547-53.
2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.
3. Lawes CM, Vanders HS, Rodgers A. Global burden of blood-pressure related disease, 2001. Lancet. 2008;371:1513-8.
4. McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005;23:S3-8.
5. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.
6. Appel LJ, Giles TD, Black HR, et al. American society of hypertension writing group: ASH position paper: dietary approaches to lower blood pressure. J Clin Hypertens. 2009;11(7):358-68.
7. Miller 3rd ER, Erlinger TP, Appel LJ. The effects of macronutrients on blood pressure and lipids: an overview of the DASH and OmniHeart trials. Curr Atheroscler Rep. 2006;8(6):460-5.
8. Pérez-López FR, Chedraui P, et al. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas. 2009;64(2):67-79.
9. Hall WL. Dietary saturated and unsaturated fats as determinants of blood pressure and vascular function. Nutr Res Rev. 2009;22(1):18-38.
10. Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol. 2009;7(3):330-7.
11. • Pase MP, Grima NA, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr. 2011;106(7):974-80. A comprehensive recent meta-analysis of randomized controlled trials on the effect of PUFAs on arterial stiffness.
12. Balakumar P, Taneja G. Fish oil and vascular endothelial protection: bench to bedside. Free Radic Biol Med. 2012;53(2):271-9.
13. Altorf-van der Kuil W, Engberink MF, Brink EJ, et al. Dietary protein and blood pressure: a systematic review. PLoS One. 2010;5(8):e12102.
14. •• Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011;25(7):425-36. A comprehensive recent meta-analysis of randomized controlled trials on the effect of lactotripeptides on human BP, with a particular focus on effect of ethnicity on the BP lowering efficacy.
15. Cicero AF, Rosticci M, Gerocarni B, et al. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertens Res. 2011;34(9):1035-40.
16. Lordan S, Ross P, Stanton C. Marine Bioactives as functional food ingredients: potential to reduce the incidence of chronic disease. Mar Drugs. 2011;9(6):1056-100.
17. Rajapakse NW, Mattson DL. Role of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharmacol Physiol. 2009;36(3):249-55.
18. • Dong JY, Qin JQ, Zhang ZL, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011;162:959-65. A comprehensive recent meta-analysis of randomized controlled trials on the effect of L-Arginine BP lowering effect.
19. Martina V, Masha A, Gigliardi VR, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008;31(5):940-4.
20. Zulli A. Taurine in cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2011;14(1):57-60.
21. Moloney MA, Casey RG, O'Donnell DH, et al. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc Dis Res. 2010;7(4):300-10.
22. Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin Nephrol. 1999;19:494-9.
23. Gu D, He J, Xigui W, Duan X, Whelton PK. Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo controlled trial. J Hypertens. 2001;19:1325-31.
24. D'Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57(10):1210-9.
25. Yang Q, Liu T, Kuklina EV, et al. Sodium and potassium intake and mortality among US adults: prospective data from the third national health and nutrition examination survey. Arch Int Med. 2011;171(13):1183-91.
26. Houston MC. The importance of potassium in managing hypertension. Curr Hypertens Rep. 2011;13(4):309-17.
27. Houston MC, Harper KJ. Potassium, Magnesium, and Calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens. 2008;10(7S2):3-11.
28. • Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr. 2012;66(4):411-8. A comprehensive recent meta-analysis of randomized controlled trials on the effect of oral magnesium supplementation BP lowering effect.
29. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J Hypertens. 2000;18:1177-91.
30. Widman L, Wester PO, Stegmayr BG, Wirell MP. The dose dependent reduction in blood pressure through administration of magnesium: a double-blind placebo-controlled cross-over trial. Am J Hypertens. 1993;6:41-5.
31. Houston MC. The role of magnesium in hypertension and cardiovascular disease. J Clin Hyperten. 2011;13(11):843-7.
32. • Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010;8:CD001059. A comprehensive recent meta-analysis of randomized controlled trials on the effect of calcium supplementation on prevention of pre-eclampsia in pregnants.
33. Garcia Zozaya JL, Padilla VM. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin aldosterone system. Invest Clin. 1997;38:27-40.
34. Bergomi M, Rovesti S, Vinceti M, et al. Zinc and copper status and blood pressure. J Trace Elem Med Biol. 1997;11:166-9.
35. Ness AR, Khaw K-T, Bingham S, Day NE. Vitamin C status and blood pressure. J Hypertens. 1996;14:503-8.
36. Enstrom JE, Kanim LE, Klein M. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3:194-202.
37. Block G, Jensen CD, Norkus EP, et al. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young black and white women. Nut J. 2008;17(7):35-46.
38. Ness AR, Chee D, Elliott P. Vitamin C and blood pressure - an overview. J Hum Hypertens. 1997;11(6):343-50.
39. Block G, Mangels AR, Norkus EP, et al. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension. 2001;37:261-7.
40. Sherman DL, Keaney JF, Biegelsen ES, et al. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension. 2000;35:936-41.
41. • Juraschek SP, Guallar E, Appel LJ, Miller 3rd ER. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;95(5):1079-88. A comprehensive recent meta-analysis of randomized controlled trials on the effect of supplemented vitamin C BP lowering effect.
42. Mahajan AS, Babbar R, Kansai N, et al. Antihypertensive and antioxidant action of amlodipine and Vitamin C in patients of essential hypertension. J Clin Biochem Nutr. 2007;402:141-7.
43. Sato K, Dohi Y, Kojima M, Miyagawa K. Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung. 2006;6(7):535-40.
44. Plantinga Y, Ghiadoni L, Magagna A, Biannarelli C. Supplementation with Vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20(4):392-7.
45. Simon JA. Vitamin C, and cardiovascular disease: a review. J Am Coll Nutr. 1992;11(2):107-25.
46. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the antihypertensive effect of dietary supplements via aldehydes reduction evidence based: A systemic review. Clin Exp Hypertens. 2008;30(7):628-39.
47. Ledlerc PC, Proulx CD, Arquin G, Belanger S. Ascorbic acid decreases the binding affinity of the AT1 Receptor for angiotensin II. Am J Hypertens. 2008;21(1):67-71.
48. Keniston R, Enriquez Sr JI. Relationship between blood pressure and plasma vitamin B6 levels in healthy middle-aged adults. Ann N Y Acad Sci. 1990;585:499-501.
49. Aybak M, Sermet A, Ayyildiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. 1995;45:1271-3.
50. van Dijk RA, Rauwerda JA, Steyn M, et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2001;21(12):2072-9.
51. Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102:1540-4.
52. •• Vaidya A, Forman JP. Vitamin D and Vascular Disease: The Current and Future Status of Vitamin D Therapy in Hypertension and Kidney Disease. Curr Hypertens Rep. 2012;14:111-9. A very interesting and complete update on epidemiological, physiopathological and interventional evidence on the role of vitamin D supplementation in hypertension and its main organ target.
53. Habauzit V, Morand C. Evidence for a protective effect of polyphenols-containing foods on cardiovascular health: an update for clinicians. Ther Adv Chronic Dis. 2012;3(2):87-106.
54. • Ried K, Sullivan TR, Fakler P, et al. Effect of cocoa on blood pressure. Cochrane Database Syst Rev. 2012;8:CD008893. A large comprehensive recent meta-analysis of randomized controlled trials on the effect of cocoa BP lowering effect, with particular attention to the content of flavanols.
55. Steffen M, Kuhle C, Hensrud D, et al. The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(12):2245-54.
56. Watanabe T, Arai Y, Mitsui Y, et al. The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin Exp Hypertens. 2006;28(5):439-49.
57. Yamaguchi T, Chikama A, Mori K, et al. Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure. Nutr Metab Cardiovasc Dis. 2008;18(6):408-14.
58. Bogdanski P, Suliburska J, Szulinska M, et al. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res. 2012;32(6):421-7.
59. Hodgson JM, Puddey IB, Woodman RJ, et al. Effects of black tea on blood pressure: a randomized controlled trial. Arch Intern Med. 2012;172(2):186-8.
60. Wahabi HA, Alansary LA, Al-Sabban AH, Glasziuo P. The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: a systematic review. Phytomedicine. 2010;17(2):83-6.
61. Li H, Xia N, Förstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide. 2012;26(2):102-10.
62. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes. 2012 Nov 28. [Epub ahead of print]
63. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011;111(8):1173-81.
64. Cicero AFG, Derosa G, Manca M, et al. Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a 6-month, randomized clinical trial. Clin Exp Hypert. 2007;29:1-12.
65. Pal S, Khoussousi A, Binns C, et al. The effects of 12 week psyllium fibre supplementation or healthy diet on blood pressure and arterial stiffness in overweight and obese individuals. Brit J Nutr. 2012;107(5):725-34.
66. Wichitsranoi J, Weerapreeyakul N, Boonsiri P, et al. Antihypertensive and antioxidant effects of dietary black sesame meal in pre-hypertensive humans. Nutr J. 2011;10:82.
67. Wu JH, Hodgson JM, Puddey IB, et al. Sesame supplementation does not improve cardiovascular disease risk markers in overweight men and women. Nutr Metab Cardiovasc Dis. 2009;19(11):774-80.
68. Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001;158(1):195-8.
69. Lynn A, Hamadeh H, Leung WC, Russell JM, Barker ME. Effects of pomegranate juice supplementation on pulse wave velocity and blood pressure in healthy young and middle-aged men and women. Plant Foods Hum Nutr. 2012;67(3):309-14.
70. Langsjoen PH, Langsjoen AM. Overview of the use of Co Q 10 in cardiovascular disease. Biofactors. 1999;9:273-84.
71. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009;4:CD007435.
72. Ankola DD, Viswanas B, Bhardqaj V, et al. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplement be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm. 2007;67(2):361-9.
73. Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas. 2011;68(4):299-310.
74. Paran E, Novac C, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants form tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc Durgs Ther. 2009;23(2):145-51.
75. Maimoona A, Naeem I, Saddiqe Z, Jameel K. A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. J Ethnopharmacol. 2011;133(2):261-77.
76. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008;28(5):315-20.
77. Liu X, Wei J, Tan F, et al. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004;74(7):855-62.
78. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186-95.
79. Rodella LF, Favero G, Foglio E, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Front Biosci. 2013;5:119-29.
80. • Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-84. A comprehensive recent meta-analysis of randomized controlled trials on the effect melatonin BP lowering effect, with a particular attention to the different effect of slow-release and immediate release formulation.
81. Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep. 2012;35(10):1395-402.
82. Butt MS, Sultan MT, Butt MS, Iqbal J. Garlic: nature's protection against physiological threats. Crit Rev Food Sci Nutr. 2009;49(6):538-51.
83. Ried K, Frank OR, Stocks NP, et al. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2008;8:13.
84. Reid K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomized controlled trial. Maturitas. 2010;67(2):144-50.
85. Wray DW, Nishiyama SK, Harris RA, et al. Acute reversal of endothelial dysfunction in the elderly after antioxidant consumption. Hypertension. 2012;59(4):818-24.
86. Rahman ST, Merchant N, Haque T, et al. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study. J Cardiovasc Pharmacol Ther. 2012;17(2):139-45.
87. Mate A, Miguel-Carrasco JL, Vázquez CM. The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. Drug Discov Today. 2010;15(11-12):484-92.
88. Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract. 2006;56(527):437-43.